Approximately 3500 children with sickle cell disease (SCD) are born in Brazil each year, but the burden of SCD morbidity is not fully characterised. A large, multi-centre cohort was established to characterise clinical outcomes in the Brazilian SCD population and create the infrastructure to perform genotype-phenotype association studies. Eligible patients were randomly selected from participating sites and recruited at routine visits. A biorepository of blood samples was created and comprehensive demographic and clinical outcome data were entered in a centralized electronic database. Peripheral blood genome-wide single nucleotide polymorphism (SNP) genotyping was performed using a customized Transfusion Medicine (TM) Array. A total of 2795 participants at six Brazilian sites were enrolled between 2013 and 2015. The cohort included slight predominance of children <18 years (55Á9%) and females (53Á0%). Haemoglobin (Hb) SS was the most common SCD genotype (70Á7%), followed by HbSC (23%), Sb0 (3Á0%) and Sb+ (2Á9%). SNP data from the TM Array were analysed to evaluate the genetic ancestry of the cohort and revealed significant admixture among the population. Demographics and clinical complications, stratified by age and SCD genotype, are summarized and future studies in this cohort are discussed.
pathophysiology of SCD is complex. It involves a combination of vaso-occlusion, haemolysis, endothelial dysfunction and inflammation, and patients with SCD suffer severe complications of virtually every organ system (Kato et al, 2017) . There is significant heterogeneity in clinical manifestations among patients with SCD, even within each SCD genotype (Saraf et al, 2014) and the ability to predict specific complications in individual patients and therefore tailor patient-specific screening and therapy is not currently possible.
In Brazil, the mutations that cause SCD were introduced during the colonial era after 1500 by the slave trade of people of African origin (Curtin, 1969) . The gene mutations causing alpha and beta thalassaemia were introduced by European populations (Salzano & Bortolini, 2002; Wagner et al, 2010) , which also mixed with the populations already present in Brazil, thus creating a genetically admixed population of SCD patients with varying heritage. Brazil currently has between 25 000 and 30 000 people with SCD and about 7 million carriers, leading to the birth of approximately 3500 infants with SCD each year, though the prevalence varies markedly across the country (Canc ßado & Jesus, 2007) .
Despite clinical guidelines and advances in SCD treatment (see Clinical Context below) in Brazil, there is no national database or organized national network to comprehensively evaluate and characterize the impact of SCD in Brazil. The Recipient Epidemiology and Donor Evaluation (REDS)-III Brazil SCD Cohort was established to define the prevalence of clinical complications with a focus on transfusion outcomes in a large sample of the Brazilian SCD population and to create the infrastructure to perform targeted studies within the cohort.
Clinical Context
Brazil has a mixed healthcare system of public and private health insurance and service provision. Universal access to care is provided by the public healthcare system, the Unified Health System (SUS), and the vast majority of patients with SCD receive care through this. The Brazilian Government, through the National Agency of Sanitary Vigilance (ANVISA) and the Blood Coordination of the Ministry of Health (MoH), implemented a series of new regulations from 2001 to 2017, requiring neonatal screening (starting in the late 1980s and now available in all 27 states) and comprehensive care of SCD (ANVISA, 2002 , Brazilian Ministry of Health, 2005 , 2012 , 2015 . Practice guidelines include:
1. Standardized use of folic acid (1-5 mg/day) and prophylactic antibiotics for children from 3 months to 5 years of age using oral penicillin V, monthly injected benzathine or erythromycin for patients with documented penicillin allergy. 2. Hydroxycarbamide (HC) is recommend for the following indications: three or more acute vaso-occlusive pain episodes (VOE) requiring hospital medical care or proven productive incapacity (school/work); >1 acute chest syndrome (ACS) event; ≥1 ACS that required ≥2 blood transfusions, ≥1 ACS that required hospitalization in an intensive care unit; chronic hypoxaemia defined as oxygen saturation persistently lower than 94% measured at two consecutive routine clinical visits; other evidence of chronic organ damage (priapism, bone necrosis, proliferative retinopathy, among others) (Brazilian Ministry of Health, 2012 Ministry of Health, 2015 .
Methods

REDS-III overview
This study is part of the international component of the multi-centre USA National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) REDS-III programme that conducts research focused on the safety and adequacy of the blood supply and impact of blood transfusion in recipients in the USA, Brazil, China and South Africa (Kleinman et al, 2014) . Multiple different research projects have been implemented through REDS-III, including studies to characterize blood product epidemiology and utilisation (Karafin et al, 2017) , the risk of human immunodeficiency virus (HIV) and other transfusion-transmitted infections primarily in international sites (Sabino et al, 2016) , identify donor characteristics that impact storage of blood (Kanias et al, 2017) , and characterize transfusion outcomes in recipients of blood (Bloch et al, 2015) . The Brazil programme is 
Patient recruitment and study procedures
A list of the 9676 active patients (patients with at least one clinical encounter in the last 3 years) at the six participating sites was created and a random sample from this list was selected by RTI. Approximately 50% of the active patient population (4956 of 9676) was enlisted as the sample frame in order to achieve a recruitment goal of 3000 participants. Randomization was conducted in strata proportional to the age (children defined as aged <18 years or adults defined as aged ≥18 years), gender and SCD genotype distributions of the patients at each haemocentre to ensure the study population was reflective of the SCD population at each site. Patients randomly selected as eligible were recruited at scheduled clinic visits. An interview, medical record abstraction and blood collection were performed for all consenting participants. The interview captured comprehensive demographics and vital signs were measured. Race was defined according to the standards of the Brazilian census, which refers to skin colour instead of heritage. Medical records were reviewed by haematologists, or research nurses under the supervision of haematologists, to abstract clinical data using standardised definitions of the phenotypic manifestations of SCD (Ballas et al, 2010) . Abstraction included any documentation in the patient's record of specific clinical events, such as stroke, avascular necrosis, priapism, leg ulcers, bacteraemia and other SCD complications which had occurred during patients' lifetime. Detailed information related to hospitalisations, transfusions, laboratory testing and screening examinations that occurred in the year prior to enrolment was also abstracted (summary of collected data in Table SI) . Transfusion history and blood bank data, including red blood cell phenotype and antibody data, were extracted from each haemocentre's records. A comprehensive electronic database was created to centralise all clinical, laboratory and transfusion information. In the current phase of the cohort, approximately annual follow-up visits are scheduled through 2018 to capture interim clinical and transfusion events. This paper presents the baseline data collected during enrolment visits in 2013-2015. Biospecimen collection and single nucleotide polymorphism genotyping A biospecimen repository of blood samples from all enrolled patients was established to complement the database and support translational studies relevant to SCD pathogenesis and transfusion complications. Blood was collected in EDTA tubes, separated into cellular and plasma components and aliquoted for storage in a Biobank held at the University of São Paulo. DNA was extracted from cellular aliquots using alcohol precipitation and quantified using real-time polymerase chain reaction (PCR). DNA was normalized to 10 ng/ll with a minimum volume of 60 ll.
Peripheral blood genomewide single nucleotide polymorphism (SNP) genotyping was performed using a customized Axiom TM array, entitled the Transfusion Medicine Array (TM Array; Affymetrix, Santa Clara, CA, USA). The TM Array was developed by REDS-III to facilitate targeted blood donor and recipient studies and includes 875 188 SNPs, of which 549 000 were designed to whole genome coverage down to a minor allele frequency (MAF) of 5% in European, African and East Asian descended populations. In addition, SNPs down to a MAF of 1% were included in 141 iron-related genes, 3856 platelet genes, 1285 red blood cell genes, 238 cytokines, 155 tumour growth factor genes and 48 genes associated with SCD-related phenotypes. The TM Array also includes~1000 copy number polymorphisms (CNPs) across alpha globin, beta globin and RH loci to allow the detection of copy number changes (Page et al, 2016) .
The DNA samples were genotyped using the TM Array in the UCSF Genomics Core Facility. SNPs were called using the Axiom Analysis Suite Software (Affymetrix Thermo Fisher Scientific, Waltham, MA, USA), HLA alleles were called with Axiom HLA Analysis software (Affymetrix) and CNPs were called with Axiom CNV Summary Tools with further analysis with PennCNV (http://penncnv.openbioinfor matics.org/en/latest/). 838 722 SNPS were considered high quality by the software. We examined for genotype mismatches between duplicate samples and excluded 6925 SNPS. Additionally, 3546 markers that were not successfully called in >97% of samples were also excluded resulting in a final data set of 831 797 SNPs.
Germany) (Ronaghi, 2001) . If pyrosequencing diagnosis matched the original haemocentre diagnosis of SS or SC, no further testing was performed. If pyrosequencing showed either SS or SC that did not match the diagnosis recorded in medical records or heterozygous S was detected, Sanger sequencing of HBB exons 1 and 2 was performed. This allowed confirmation of SS or SC diagnosis and defined the specific b0 or b+ mutations for most Sb thalassaemia subjects. Samples from 26 participants with an unresolved sickle cell genotype after sequencing were sent to the Hemoglobinopathy Reference Laboratory at UCSF Benioff Children's Hospital Oakland (CHO) for definitive diagnosis. Sequencing at CHO included HBB exon 3 in addition to introns and promoter regions, and SCD genotype was resolved in all 26 participants. For data analyses of clinical complications, genotypes SS, Sb0, SD and S/Quebec-CHORI were combined to create a single sickle cell anaemia (SCA) category.
Statistical methods
Statistical analyses were performed by RTI, using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA). Continuous variables are reported as medians (interquartile range) or means (standard deviation), depending on the distribution, while categorical variables are summarized as number (%). Differences between haemocentres and sickle cell type groups were assessed using analysis of variance (ANOVA) or Kruskal-Wallis tests as appropriate, for continuous variables; and chi square test or Fishers exact test as appropriate for categorical variables.
The TM Array SNP data were analysed to evaluate the genetic ancestry background of the cohort compared to selfreported skin colour using the categories established by the Brazilian Census. A random set of 100 000 common markers (minor allele frequency 5%) was extracted from the REDS-III Brazil SCD cohort and the 1000 Genomes Project (1000G) phase three release May 2013 (Auton, 2015) . Principle component analyses (PCA) were conducted using PLINK version 1.90a (Purcell et al, 2007) . Principle components were extracted and plotted using the ggplot2 (v2.2.1) package in R (v3.2.5) (https://CRAN.R-project.org/package=ggplot2). T-tests were conducted to compare the mean of principle components between subgroups of the cohort by self-reported skin colour. For both clinical and PCA comparisons, a P value of <0Á01 was defined as statistically significant, considering multiple outcomes were compared.
Results
Demographics
Of the 4956 randomly selected eligible patients, 3029 were recruited in the defined enrolment period from 2013 to 2015 and 2795 participants (92Á3% of recruited patients) were enrolled in the cohort. Of 3029 recruited patients, 234 were not included in the cohort either because the participant decided he/she was not interested (n = 218) or the patient was excluded when further evaluation revealed the patient did not have SCD (n = 16).
In the enrolled cohort, there were slightly more children <18 years old (55Á9%) than adults and slightly more females (53Á0%) than males. The majority of the patients reported being mixed skin colour (58Á7%) or black (26Á8%), with significant variation in self-reported skin colour among the participating centres. Only 34Á2% of the adults ≥18 years of age reported current employment and most patients (93Á5%) reported a monthly household income of ≤$3000 Brazilian reals (approximately $1351 US dollars in 2014). Most adult patients (82Á2%) did not have more than secondary (high) school-level education (6Á5% had attended post-secondary technical school (public schools, equivalent to a high school level, but with additional hours to learn a specific skill, such as electronics, computation, clinical laboratory, etc., to work as a technician in industry, laboratories, hospitals and services) and 11Á3% had attended college (Table I) .
Most patients had HbSS (1976 of 2795, 70Á7%), but the genotypes varied among the six clinical centres, with the highest prevalence of SS in Hemope in the State of Pernambuco (83Á5% , Table I ). Patients with HbSC accounted for 23% of the cohort, but again with uneven distribution among the regions studied, with the three sites in the state of Minas Gerais having the highest prevalence (28Á8-33Á6%). The prevalences of Sb+ (2Á9%) and Sb0 (3Á0%) were lower among the patients enrolled and other heterozygous forms of SCD such as SD and other variants were rare (0Á4%). Demographics of the study population enrolled at each haemocentre did not significantly differ from those of the overall active SCD population at the centre (data not shown). Comprehensive demographics are summarized in Table I , with socioeconomic data restricted to adults aged ≥18 years.
TM Array data
Comparison of the TM Array data from the enrolled participants to the 1000G revealed the REDS-III Brazil SCD cohort is a heterogeneous population (Fig 1) . Varying levels of heterogeneity were observed within each self-reported skin colour (as a surrogate for race based on Brazilian census categories). However, patients who self-reported as white were significantly more similar to 1000G Caucasians than other members of the Brazil SCD populations (P < 0Á0001); similarly, self-reported black patients were significantly more similar to 1000G Africans (P < 0Á0001) as supported by the first principle component. Patients reporting other skin colours were distributed between the white and black groups. The self-reported Indigenous category in the SCD cohort did not correspond with Native American populations, but the 1000G samples do not include representation of any subAmazonian Native American populations. Patients with Sb+/ Sb0 were more likely to report white skin colour than other genotypes (23Á8% compared to 9Á9%, P < 0Á0001). 
180 (65Á7) 228 (62Á8) 459 (83Á5) 557 (77Á4) 77 (73Á3) 1976 ( 267 (48Á5) 405 (56Á3) 105 (100) 1562 ( All P values for comparisons of haemocentre specific differences. *Same P-value excluding and including HCFMUSP. †Excluding HCFMUSP. ‡2 refused to answer, 4 did not complete the patient interview. §Includes 6 SD, 3 S/HPFH, 1 S/K-Woolwich, 1 S/Quebec-CHORI Brazilian school categories include primary (elementary), secondary (high school) and technical school (post secondary school that provides education regarding specific skills such as electronics, clinical laboratory etc.) ¶Questions asked of adult patient category only.
Disease modifying therapies, clinical complications and steady state laboratory values
Summary of the treatments, surgeries and clinical complications of the cohort participants, stratified by children/adults and SCD genotype are shown in Table II . To evaluate differences among the six participating centres, comparisons were restricted to SCA patients for all outcomes and summarized in Table SII . Treatment with HC was reported in 458 children (29Á3% of 1104) and 447 adults (36Á3% of 1044) at the time of enrolment, with a significantly higher percentage of SCA patients treated with HC than other SCD types (Table II) . The proportion of patients treated with HC varied significantly across the centres, both in children (range from 15Á4% of SCA children in Montes Claros to 57Á1% in São Paulo) and adults (range from 23Á4% of SCA adults in Montes Claros to 53Á7% in Belo Horizonte, Table SII ). Most cohort patients (75Á0% of children and 89Á2% of adults) had been transfused at least once, with significantly more SCA patients demonstrating a history of transfusion (children 88Á0%, adults 95Á9%) than SC (children 41Á3%, adults 66Á0%, Table II ). 10Á6% of children and 9Á2% of adults were treated with chronic transfusion therapy (approximately monthly red blood cell transfusion to prevent severe complications of SCD), almost all of which were SCA patients (Table II) .
Mirroring the results of chronic transfusion therapy, the use of iron chelators was similar in children (6Á1%) and adults (7Á2%) and was significantly higher in patients with SCA (8Á5% children, 9Á1% adults). The majority of the chelated patients (174/185, 94Á0%) were treated with Desferasirox â . 
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Many complications were relatively rare in children but became common by adulthood. For example, avascular necrosis (AVN) and leg ulcers were reported in only 3% and 0Á7%, respectively, of children but reached a prevalence of 15Á8% and 17Á8% in the adult population. Similarly, treatment with antidepressant drugs and antihypertensive treatment were not common in children (1Á7% and 1Á5%, respectively) but were used in 6Á9% and 13Á1% of adults. Less significant differences between the paediatric and adult population was seen in the prevalence of bacteraemia/sepsis, which occurred in 5Á2% of children and 6Á5% of adults. Differences in the prevalence of selected SCD complications and treatments in age categories of the REDS-III patients are shown in Fig 2. The use of chronic pain medication (defined as 30+ consecutive days of treatment with any analgesic in the year prior to enrolment) was significantly higher in SCA patients, both in children and adults, but was present also in SC and Sb+ patients (10Á4% of all children and 13Á8% of all adults), and was more commonly used in Hemorio than other centres. Prophylactic antibiotics were used by the majority (85Á8%) of the children aged 0-5 years in the cohort and showed some variation among the centres, with Montes Claros having the highest level of use (93Á5% of the children, Table II ).
The most commonly reported surgery in the paediatric population was splenectomy (217 children, 15Á2%). The proportion of adults with splenectomy was only 6Á6%, probably reflecting a combination of changes in clinical practice, with splenectomy being less common in the past, and also some survival bias of the cohort, with splenectomised adults potentially less likely to be alive and included in the cohort. In adults, history of cholecystectomy was the most commonly recorded surgery (378 adults, 39Á7%). Both surgeries were most common in SCA patients.
Almost one-third of both children and adults had been hospitalised in the year prior to enrolment. Hospital admissions varied by centre, with São Paulo having the highest (42Á9%) proportion of children with a hospitalisation in the year prior to enrolment, and Recife and Juiz de Fora the highest for adults (46Á0% and 36Á6%, respectively). Montes Claros had the lowest rates for hospital admissions, both in children and adults (25Á4% and 17Á8%, respectively). The most common indications for hospitalization based on discharge diagnoses abstracted from the medical records (up to three recorded for each hospitalization) in both children and adults were VOE (61Á3% of paediatric and 80Á1% of adult hospitalisations) followed by ACS (40% of paediatric and 16Á3% of adult hospitalisations). Clinically overt ischaemic stroke had occurred in 6Á3% of all children (8Á8% of SCA) and 9Á2% of all adults (10Á9% of SCA). Haemorrhagic stroke was reported to a lesser extent (less than 1Á0%) in both children and adults with SCA (Table II) .
As expected clinically, SCA patients had lower steady state haemoglobin and higher steady state white blood cell and platelet counts as well as higher levels of markers of haemolysis ACE, angiotensin-converting-enzyme; ACS, acute chest syndrome; RBC, red blood cell; SCA, sickle cell anaemia; SCD, sickle cell disease; VOE, vaso-occlusive pain episode. *Includes SS, Sb0, SD, S/Quebec-CHORI. †Less severe genotype variants such as S/HFFH and S/K-Woolwich were included with Sb+ patients. ‡Medications specifically included on study abstraction forms. §Denominators for percentages are restricted to participants ≤6 years of age.
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ª 2018 British Society for Haematology and John Wiley & Sons Ltd compared to SC or Sb+ patients (steady state was defined as laboratory values taken at routine visits, with no acute event or transfusion in the previous 2 months, Table III ).
Discussion
The REDS-III Brazil SCD cohort was established to characterize clinical outcomes with a focus on transfusion outcomes in the Brazilian SCD population and create the infrastructure to perform genotype-phenotype association studies. This report of the baseline demographics and clinical complications of the REDS-III participants highlights some similarities to other international cohorts of SCD. For example, the demographic profile of the REDS-III cohort reveals the SCD population in Brazil has higher rates of unemployment, lower monthly household income and lower education level when compared to the general population in the country (https://brasilemsintese.ibge.gov.br/educacao.html; https:// agenciadenoticias.ibge.gov.br/agencia-noticias/2013-agenciade-noticias/releases/15693-pnad-continua-taxa-de-desocupaca o-cai-em-11-das-27-ufs-no-2-trimestre-de-2017.html), underscoring the challenges faced by this vulnerable population coping with a chronic disease. The socioeconomic and educational status of the Brazilian population varies according to the region of the country, especially when the Northeastern and Southeastern parts of the country are considered (https://ww2.ibge.gov.br/home/estatistica/indicadores/trabalho erendimento/pnad_continua/default_renda_percapita.shtm). We observed differences in the SCD population among the studied centres which were comparable to differences observed in the general population, i.e., the patients in the Northeast region of Brazil and northern part of Minas Gerais State reported lower socioeconomical status indicators. The observed unemployment rate in the cohort (65Á7%) is considerably higher than the general population of Brazil, which was 6Á3-9% according to 2013-2015 Brazilian Institute of Geography and Statistics data (https://agenciadenoticias.ibge.gov.br/ agencia-noticias/2013-agencia-de-noticias/releases/15693-pnadcontinua-taxa-de-desocupacao-cai-em-11-das-27-ufs-no-2-trime stre-de-2017.html). Similarly, the monthly household income of ≤3000 Brazilian reals, reported in most patients in this cohort, is less than the household monthly income of 5072 Brazilian reals in the general population during the same time period (https:// ww2.ibge.gov.br/home/estatistica/indicadores/trabalhoerendime nto/pnad_continua/default_renda_percapita.shtm). These challenges are common to SCD patients in other parts of the world, however the unemployment rates in this Brazilian SCD cohort are even higher than the~30-50% unemployment reported in various US and Jamaican studies (Sanger et al, 2016; Asnani et al, 2017) . Additional similarities to other large SCD cohorts include the increasing prevalence of most clinical complications with age (Farber et al, 1985; Makani et al, 2011) , demonstrating the chronic cumulative organ damage experienced by SCD patients over their lifetime, and the more prevalent occurrence of most clinical phenotypes in patients with SCA compared to other genotypes (Ohene-Frempong et al, 1998) . A notable exception to this trend was the prevalence of avascular necrosis, which occurred more commonly in SC than other genotypes. Use of antihypertensives and antidepressant medications did not differ between the genotype groups.
Although heterogeneity in the clinical presentation of the Sb+ genotype is well reported, depending on the specific b+ mutation and quantity of normal HbA (Christakis et al, 1991) , Sb+ is generally associated with milder disease severity. However, the Sb+ patients in the REDS-III Cohort appear to exhibit a more severe phenotype, particularly in complications related to pain (treatment with chronic pain medication, vaso-occlusive pain hospitalisations), which were observed as frequently in Sb+ patients as SCA patients. An analysis of complications in Sb+ participants within categories of specific b+ mutations is underway to further characterize these enrolment findings.
Other differences observed in the cohort may be related to regional and clinical care differences among the patient populations studied within Brazil. The most common genotype in the REDS-III patients was SS (70Á7%), but the frequency of genotypes varied by centre, with the prevalence of SC much higher in the three sites in the state of Minas Gerais, consistent with the overall SCD population in the state. We observed variation in the rates of many treatments, including episodic and chronic transfusions among the centres that may reflect better access to care for the patients in larger metropolitan centres of the Southeast part of the country. We also cannot exclude variation among the participating centres on the utilization of the national protocols of SCD treatment instituted by the Brazilian Ministry of Health. In addition, the possibility of bias in the data exist due to missing information from clinical encounters that occurred outside the participating sites. While the centres in São Paulo, Rio de Janeiro and Recife have hospitals attached to them and patients at these centres receive both outpatient and inpatient care at the same location, the three Hemominas centres have more fragmented inpatient care and therefore data to related to hospitalisations may be less complete, especially for adult patients. The lower prevalence of complications, such as ischaemic stroke, in the oldest age group (Fig 2) may reflect survival bias to some extent, but missing data from adults' remote medical history is also likely.
An additional source of bias could result from including patients more frequently seen at the haemocentres in the study. Although a random sampling of each haemocentres' population was made to select eligible patients and attempt to obtain a representative spectrum of disease severity in the cohort, patients with milder clinical disease may not attend routine care appointments as frequently and may therefore be underrepresented.
Despite these limitations, this is one of the largest contemporary SCD cohorts in the world, and a significant strength of the cohort will be to define SCD outcomes in the current era of increased HC and chronic transfusion therapy. Approximately a third of the REDS-III cohort was treated with HC and the impact of HC in the cohort is currently being evaluated. With respect to transfusion, even with variation in the use of chronic transfusions among centres, the proportion of the REDS-III cohort treated with chronic transfusions at the time of enrolment (approximately 10%) is similar to a recent survey of 31 USA institutions collectively treating 12 644 SCD patients that reported 1274 (10%) were chronically transfused (Kelly et al, 2016 ).
An additional strength of the cohort is the extensive genotyping performed which will allow broad genotype-phenotype association studies. Whole genome SNP typing was planned as part of REDS-III with the primary goal to identify genetic determinants of red blood cell alloimmunization. Additional genotype-phenotype associations studies are underway to investigate genetic determinants of stroke, fetal haemoglobin, frequent pain and other key SCD phenotypes. These genome wide association studies will be conducted in one of the most genetically admixed populations in the world due to the combination of the Native South American, African, Caucasian and other immigrant populations in Brazil. The most commonly reported race in the REDS-III SCD patients was "mixed" and, regardless of self-reported race, significant admixture was seen when comparing the cohort to the 1000G reference populations. The admixture in Brazil is significantly more complex than SCD populations in North America (Solovieff et al, 2011) therefore this initial analysis of the population structure is critical to provide context for genotype-phenotype association studies currently underway.
The REDS-III Brazil SCD cohort was established to define the clinical impact of SCD in the Brazilian population in the current era. These data provide the context to targeted analyses currently underway to characterise blood utilisation and predictors of transfusion adverse events, identify changes in SCD pathophysiology that occur over time with chronic transfusion therapy, define the prevalence of eligible candidates for haematopoietic stem cell transplant based on recent MoH guidelines, identify predictors of severe pain and characterize the prevalence and risk factors for infectious diseases, such as HIV, Hepatitis and, more recently, Zika Virus and yellow fever virus in this vulnerable population. In addition, genotype-phenotype analyses to identify the genetic determinants of key SCD complications are planned. After enrolment commenced, REDS-III was selected to participate in the NHLBI-funded Trans-Omics for Precision Medicine (TOPMed) study. The TOPMed programme provides whole genome sequencing (WGS) data to well-phenotyped cohorts in order to link WGS data to clinical outcomes and ultimately promote discoveries about the fundamental mechanisms that underlie heart, lung, blood and sleep disorders.
In conclusion, we have successfully established a large cohort representative of the range of SCD genotypes found in Brazil and defined the baseline demographic, clinical and laboratory characteristics at the time of enrolment. Given Brazil's position as a high middle-income country, this cohort provides a unique opportunity to provide broad insights into SCD and predictors of outcomes for patients relevant to low-, middle-and high-income countries with large numbers of SCD patients. We anticipate these results will be critical for defining the impact of SCD in the Brazilian population and ultimately will help guide management and research for SCD patients worldwide.
